Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
95% of athletes are diagnosed and treated for non-invasive heart disease, such as heart attacks or seizures, or implantable cardioverter defibrillator (ICD) shock.
Read Full NewsShroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.
Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.
1.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
2.
Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.
3.
Even after a partial ban, asbestos is still used and is a deadly carcinogen, according to the EPA.
4.
Making informed decisions and managing regret after prostate cancer treatment
5.
Scientists identify dual protein targets to weaken pancreatic cancer defenses
1.
Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role
2.
Gut microbiota in curing cancer
3.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
4.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
5.
Unlocking the Potential of Etoposide: A Novel Approach to Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
4.
Updates on the First Line Management of ALK+ NSCLC
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge